![]() Throughout her career, Bryan helped develop, launch and commercialize many products including blockbusters (Zantac, Levitra), major biologics (Tysabri) and orphan drugs for rare diseases (Valstar for bladder cancer, Supprelin LA for central precocious puberty), and helped establish franchises in a wide variety of therapeutic areas, including Oncology, Anti-infectives, GI and Autoimmune (MS, CD). She then went on to serve in a number of executive leadership positions in specialty pharmaceuticals and smaller, start-up biotech companies, including Indevus Pharmaceuticals and NPS Pharmaceuticals. Prior to joining BioFlorida as its President and CEO in 2013, Bryan began her career with major pharmaceutical companies including Merck, GlaxoSmithKline and Bayer Pharmaceuticals. I am encouraged by the potential of Ampligen and look forward to leveraging my experience and expertise to help unlock value in the near and long-term,” added Bryan. I am pleased to join the Board at this pivotal time and play what I believe will be an additive role as the Company progresses. “AIM demonstrates an exciting opportunity in the life sciences sector with its Ampligen asset. ![]() I look forward to working closely with Nancy as we move Ampligen toward late-stage development.” She also advances our goal to promote diversity on our board. Her addition will provide us with valuable industry connections, financial insights and business acumen as we continue to guide AIM through its next phase of growth. Bryan as an independent Director, particularly with the depth and breadth of her product marketing and commercialization expertise. William Mitchell, MD, PhD, Professor of Pathology, Microbiology and Immunology at the Vanderbilt University School of Medicine, and Chair of AIM’s Board of Directors, commented, “I am thrilled to add Ms. Bryan is the current President and CEO of BioFlorida Inc., an association supporting the advancement of life sciences in Florida. She has served on executive leadership teams and played key roles in companies’ successes, including marketing, sales, business development, financing and communications. ![]() She has also been named to a number of committees.īryan is an established leader with more than 25 years of experience in the life sciences industry. Bryan as the newest member of its Board of Directors. ( NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases - including COVID-19, the disease caused by the SARS-CoV-2 virus - today announced Nancy K. Brain fog describes the short-term memory loss, difficulty concentrating, and confusion occurring in some patients with long Covid.OCALA, Fla., Ma(GLOBE NEWSWIRE) - AIM ImmunoTech Inc. Meanwhile, a PROMIS questionnaire for cognition could serve as a secondary endpoint for the long Covid symptom of brain fog, McAleer notes. The trial could also measure the 6-Minute Walk Test (6MWT), which the FDA recognises as a measure of fatigue and exercise capacity, he adds. In AIM ImmunoTech’s planned Phase II trial, the company will specifically focus on symptoms of fatigue and exercise capacity, McAleer says.Īs a Phase II trial endpoint, AIM ImmunoTech could use the PROMIS fatigue score, an FDA-approved, self-reported questionnaire assessing fatigue levels, McAleer explains. Long Covid describes the constellation of symptoms patients can experience at least a month after an acute Covid-19 infection. “We believe that this pilot study-where we’re getting basically 100% response in a very small sample-compels us to move into a randomised, placebo-controlled, double-blind trial to test Ampligen in this serious unmet need,” Equels explains. The trial was originally designed for patients with chronic fatigue syndrome (CFS) but expanded to include some patients with long Covid symptoms of fatigue. On July 28, AIM ImmunoTech reported positive results for four patients with long Covid receiving Ampligen as part of an expanded access study ( NCT00215813).
0 Comments
Leave a Reply. |